As we continue to educate key stakeholders around the benefits of azetukalner, Xenon will have an increased presence at the ...

Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025– Long-term azetukalner results from X-TOLE open-label ...

Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around ...

According to Future Market Insights (FMI), growing demand for rare gases across the globe for various applications is ...

Xenon's discovery concluded an intense period of research on noble gases. Much heavier than neon and krypton, it had not been explicitly predicted, and was sufficiently rare to avoid chance detection ...